X

Trial Profile

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tinzaparin sodium (Primary)
Indications Thrombosis; Venous thromboembolism
Focus Therapeutic Use
Acronyms PROTHROMCOVID

Most Recent Events

29 Aug 2022 Results (n=300) assessing the efficacy and safety of tinzaparin in prophylactic, intermediate and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
24 Feb 2022 Status changed from recruiting to completed.
27 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com